## Allan J Jacobs

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4607197/publications.pdf

Version: 2024-02-01

	394286	414303
1,073	19	32
citations	h-index	g-index
		10.4
55	55	494
docs citations	times ranked	citing authors
	1,073 citations  55 docs citations	1,073 19 citations h-index  55 55

#	Article	IF	CITATIONS
1	What We Owe Parents and Family. The International Library of Bioethics, 2022, , 71-93.	0.1	o
2	The State Intervention Test: When to Interfere with Parental Decisions. The International Library of Bioethics, 2022, , 131-146.	0.1	0
3	Female Genital Alteration. The International Library of Bioethics, 2022, , 277-292.	0.1	1
4	Prevention and Screening. The International Library of Bioethics, 2022, , 165-181.	0.1	0
5	Male Circumcision. The International Library of Bioethics, 2022, , 259-275.	0.1	2
6	Political Considerations in a Liberal Pluralist State. The International Library of Bioethics, 2022, , 109-129.	0.1	0
7	Males and females have different anatomy: is this relevant to circumcision? A reply to †The prosecution of Dawoodi Bohra women' by Richard Shweder. Global Discourse, 2022, 12, 77-89.	0.4	2
8	Is Physical Alteration a Sufficient Reason to Prohibit Ritual Infant Circumcision?. Journal of Religion and Health, 2021, 60, 1672-1693.	0.8	9
9	Immediate Complications of Elective Newborn Circumcision. Hospital Pediatrics, 2018, 8, 615-619.	0.6	17
10	Best Interests or Harm to Reverse Parental Decisions: Each in Its Own Domain. American Journal of Bioethics, 2018, 18, 41-44.	0.5	10
11	When may government interfere with religious practices to protect the health and safety of children?. Ethics, Medicine and Public Health, 2018, 5, 86-93.	0.5	9
12	Refusal of Vaccination: A Test to Balance Societal and Individual Interests. Journal of Clinical Ethics, 2018, 29, 206-216.	0.1	3
13	Punishment of Minor Female Genital Ritual Procedures: Is the Perfect the Enemy of the Good?. Developing World Bioethics, 2017, 17, 134-140.	0.6	17
14	Vulvar Nick and Metzitzah b'peh: Punishment or Harm Reduction?. , 2017, , 151-169.		3
15	Use of a Balanced Test to Resolve Competing Best Interest and Liberty Claims When Parents Refuse Consent for Neonatal Pulse Oximetry. American Journal of Bioethics, 2016, 16, 28-29.	0.5	1
16	Female genital alteration: a compromise solution. Journal of Medical Ethics, 2016, 42, 148-154.	1.0	61
17	Ritual Male Infant Circumcision and Human Rights. American Journal of Bioethics, 2015, 15, 30-39.	0.5	40
18	Response to Open Peer Commentaries on "Ritual Male Infant Circumcision and Human Rights― American Journal of Bioethics, 2015, 15, W1-W4.	0.5	0

#	Article	IF	Citations
19	Response to "The Mysterious Disappearance of the Object of Inquiry: Jacobs and Arora's Defense of Circumcision― American Journal of Bioethics, 2015, 15, W4-W5.	0.5	1
20	The ethics of circumcision of male infants. Israel Medical Association Journal, 2013, 15, 60-5.	0.1	16
21	Exclusive breastfeeding rates in a multiethnic population at a community hospital. Journal of reproductive medicine, The, 2011, 56, 195-8.	0.2	1
22	Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil®): Experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer. Annals of Oncology, 2007, 18, 716-721.	0.6	74
23	Diagnostic X-Rays and Risk of Epithelial Ovarian Carcinoma in Jews. Annals of Epidemiology, 2002, 12, 426-434.	0.9	11
24	Epidemiology of Injuries by Needles and Other Sharp Instruments: Minimizing Sharp Injuries in Gynecologic and Obstetric Operations. Surgical Clinics of North America, 1995, 75, 1105-1121.	0.5	32
25	A Phase II Trial of Didemnin B (NSC #335319) in Patients with Previously Treated Epithelial Ovarian Cancer A Gynecologic Oncology Group Study. American Journal of Clinical Oncology: Cancer Clinical Trials, 1993, 16, 47-49.	0.6	25
26	A phase II trial of didemnin B (NSC No. 325319) in advanced and recurrent cervical carcinoma: A Gynecologic Oncology Group study. Gynecologic Oncology, 1992, 44, 268-270.	0.6	16
27	Incisional recurrence of squamous cell cervical carcinoma following operative staging. Gynecologic Oncology, 1990, 39, 232-235.	0.6	24
28	A rapid DNA probe test for detecting human papilloma virus types and 16 in biopsy specimens. Molecular and Cellular Probes, 1989, 3, 273-288.	0.9	6
29	Mullerian adenosarcoma of the cervix with heterologous elements: Diagnostic and therapeutic approach. Gynecologic Oncology, 1989, 32, 381-384.	0.6	26
30	Inhibition of proliferation of lines derived from human cervical carcinomas by cytotoxic drugs and by recombinant interferons. Gynecologic Oncology, 1989, 32, 31-36.	0.6	10
31	Phase I/II Study of Definitive Radiotherapy and Chemotherapy (Cisplatin and 5-Fluorouracil) for Advanced or Recurrent Gynecologic Malignancies. American Journal of Clinical Oncology: Cancer Clinical Trials, 1989, 12, 467-473.	0.6	32
32	Serum copper in ovarian carcinoma. Cancer, 1988, 61, 1015-1017.	2.0	2
33	Therapy of ovarian carcinoma: The relationship of dose level and treatment intensity to survival. Gynecologic Oncology, 1988, 31, 233-245.	0.6	8
34	Letter to the editor. Gynecologic Oncology, 1986, 25, 256-258.	0.6	4
35	Treatment of Carcinoma of the Fallopian Tube Using Cisplatin, Doxorubicin, and Cyclophosphamide. American Journal of Clinical Oncology: Cancer Clinical Trials, 1986, 9, 436-439.	0.6	26
36	Serum levels of CA-125 in patients with endometriosis: a preliminary report. Fertility and Sterility, 1986, 45, 876-878.	0.5	56

#	Article	IF	Citations
37	Short-term persistence of carcinoma of the uterine cervix after radiation. An indicator of long-term prognosis. Cancer, 1986, 57, 944-950.	2.0	50
38	Carcinoma of the fallopian tube: Management and sites of failure. Cancer, 1986, 58, 2070-2075.	2.0	91
39	Complications in patients receiving both irradiation and radical hysterectomy for carcinoma of the uterine cervix. Gynecologic Oncology, 1985, 22, 273-280.	0.6	11
40	Chemical induction of ovarian epithelial carcinoma in mice. Gynecologic Oncology, 1984, 18, 177-180.	0.6	6
41	Breast Carcinoma Met Astatic to the Vagina. Acta Obstetricia Et Gynecologica Scandinavica, 1983, 62, 83-85.	1.3	3
42	Pure Choriocarcinoma of the Ovary. Obstetrical and Gynecological Survey, 1982, 37, 603-609.	0.2	54
43	Diagnostic significance and sequelae of cone biopsy. American Journal of Obstetrics and Gynecology, 1982, 143, 312-318.	0.7	16
44	Histologic correlates of virulence in ovarian adenocarcinoma. American Journal of Obstetrics and Gynecology, 1982, 143, 574-580.	0.7	20
45	Histologic correlates of virulence in ovarian adenocarcinoma. American Journal of Obstetrics and Gynecology, 1982, 144, 885-889.	0.7	26
46	Combination chemotherapy of ovarian granulosa cell tumor with cis-platinum and doxorubicin. Gynecologic Oncology, 1982, 14, 294-297.	0.6	60
47	Intestinal perforation during pregnancy. International Journal of Gynecology and Obstetrics, 1982, 20, 335-339.	1.0	1
48	Chemotherapy of advanced and recurrent endometrial carcinoma with cyclophosphamide, doxorubicin, 5-fluorouracil, and megestrol acetate. American Journal of Obstetrics and Gynecology, 1981, 140, 313-316.	0.7	32
49	Transformation of endodermal sinus tumor to dysgerminoma following chemotherapy. American Journal of Obstetrics and Gynecology, 1981, 139, 970-972.	0.7	3
50	Intraperitoneal infusion of doxorubicin in the treatment of gynecologic carcinomas. Medical and Pediatric Oncology, 1981, 9, 245-250.	1.0	28
51	Pseudo-Meigs Syndrome with Resulting Papillary Adenocarcinomas of the Ovary and Fallopian Tube. International Journal of Gynecology and Obstetrics, 1980, 18, 170-171.	1.0	15
52	Oat cell carcinoma of the uterine cervix in a pregnant woman treated with cis-diamminedichloroplatinum. Gynecologic Oncology, 1980, 9, 405-410.	0.6	79
53	A comparison of the antiemetic effects of droperidol and prochlorperazine in chemotherapy with cis-platinum. Gynecologic Oncology, 1980, 10, 55-57.	0.6	33